Accelerating Discovery,Transforming Medicine
From target identification to clinical trials, Gimerny AI compresses the drug discovery timeline from decades to months using graph neural networks, generative molecular design, and multi-omics intelligence.
The Gimerny AI Platform
Five integrated products covering every stage of the drug discovery pipeline, from target to trial.
GimernyDiscover
Identify and validate novel drug targets with unprecedented accuracy using knowledge graphs, graph neural networks, and multi-omics data integration.
GimernyGenome
Unify genomic, transcriptomic, proteomic, and metabolomic data into actionable insights using foundation models trained on petabytes of biological data.
GimernyMolecule
Design novel drug candidates with optimized properties using 3D-aware diffusion models, reinforcement learning, and physics-informed scoring.
GimernySynth
Predict optimal synthesis routes for any molecule using transformer-based retrosynthesis, reaction prediction, and automated route optimization.
GimernyTrial
Optimize clinical trial design, patient stratification, and endpoint selection using causal ML, digital twins, and real-world evidence analysis.
Watch the Platform in Action
Our real-time molecular generation engine creates optimized drug candidates in seconds, not months. Each molecule is scored against 21 ADMET endpoints, docked against the target structure, and ranked by synthetic feasibility.
Real-Time Generation
3D-aware diffusion models produce novel molecules conditioned on your target pocket
Instant ADMET Scoring
21 ADMET endpoints evaluated simultaneously, flagging liabilities before synthesis
Synthesis-Ready Output
Every molecule comes with a ranked list of synthesis routes from GimernySynth
From Target to Trial in Months
Our integrated platform covers every stage of the drug discovery pipeline, with each product feeding data to the next.
Discover
AI-Driven Target Identification
Genome
Multi-Omics Intelligence Platform
Molecule
Generative Molecular Design
Synth
AI-Powered Synthesis Planning
Trial
Clinical Trial Intelligence
Latest from the Lab
Research, engineering, and industry insights from our team.
Why Equivariant Diffusion Models Are Reshaping Drug Design
Traditional virtual screening searches existing chemical libraries. Generative models create entirely new molecules, but only if they respect the 3D symmetries of molecular interactions.
Building Biomedical Knowledge Graphs for Target Identification at Scale
How we constructed a 2.1 billion edge knowledge graph that connects proteins, genes, diseases, and drugs, and why heterogeneous GNNs are essential for reasoning over it.
Federated Learning in Pharma: Training on Patient Data Without Seeing It
How Gimerny enables multi-institutional model training while keeping sensitive patient data behind institutional firewalls, maintaining HIPAA and GDPR compliance.
Ready to Accelerate Your Pipeline?
Join 45+ pharmaceutical and biotech companies using Gimerny AI to discover better drugs, faster.